Edition:
United States

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

154.00EUR
11:35am EDT
Change (% chg)

€1.25 (+0.82%)
Prev Close
€152.75
Open
€151.50
Day's High
€154.50
Day's Low
€151.50
Volume
507,156
Avg. Vol
440,364
52-wk High
€155.50
52-wk Low
€74.48

Latest Key Developments (Source: Significant Developments)

Gilead And Galapagos Enter Into Transformative Research And Development Collaboration
Sunday, 14 Jul 2019 01:00pm EDT 

July 14 (Reuters) - Galapagos Nv ::GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION.GILEAD TO MAKE $3.95 BILLION UPFRONT PAYMENT AND $1.1 BILLION EQUITY INVESTMENT.GILEAD GAINS ACCESS TO GALAPAGOS' DIFFERENTIATED DRUG DISCOVERY PLATFORM AND CURRENT AND FUTURE PIPELINE OUTSIDE OF EUROPE.INVESTMENT ENABLES GALAPAGOS TO EXPAND AND ACCELERATE RESEARCH AND CLINICAL PROGRAMS.GALAPAGOS GAINS BROADER COMMERCIALIZATION ROLE FOR FILGOTINIB IN EUROPE AND AGREES TO SHARE EQUALLY IN FUTURE DEVELOPMENT COSTS.GILEAD AGREES TO 10-YEAR STANDSTILL.GILEAD SCIENCES AND GALAPAGOS ENTERED INTO A 10-YEAR GLOBAL RESEARCH AND DEVELOPMENT COLLABORATION.GALAPAGOS WILL USE PROCEEDS TO EXPAND AND ACCELERATE ITS RESEARCH AND DEVELOPMENT PROGRAMS.GILEAD AND GALAPAGOS HAVE AGREED TO AMEND CERTAIN TERMS IN AGREEMENT GOVERNING FILGOTINIB.CO TO HAVE GREATER INVOLVEMENT IN FILGOTINIB'S GLOBAL STRATEGY AND PARTICIPATE MORE BROADLY IN COMMERCIALIZATION OF PRODUCT IN EUROPE.GILEAD'S EQUITY INVESTMENT WILL CONSIST OF A SUBSCRIPTION FOR NEW GALAPAGOS SHARES AT A PRICE OF EUR 140.59 PER SHARE.EQUITY INVESTMENT WILL INCREASE GILEAD'S STAKE FROM APPROXIMATELY 12.3% TO 22% OF ISSUED AND OUTSTANDING SHARES IN GALAPAGOS.CO INTENDS TO SEEK SHAREHOLDER APPROVAL TO ISSUE TWO WARRANTS ALLOWING GILEAD TO FURTHER INCREASE ITS OWNERSHIP TO UP TO 29.9% OF CO.DEAL ALSO INCLUDES 10-YEAR STANDSTILL RESTRICTING GILEAD'S ABILITY TO SEEK TO ACQUIRE GALAPAGOS OR INCREASE ITS STAKE BEYOND 29.9% OF CO.  Full Article

Galapagos: Gilead Plans To Submit New Drug Application For Filgotinib To FDA
Tuesday, 2 Jul 2019 01:00am EDT 

July 2 (Reuters) - Galapagos NV ::GILEAD ANNOUNCES INTENT TO SUBMIT NEW DRUG APPLICATION FOR FILGOTINIB TO U.S. FOOD AND DRUG ADMINISTRATION THIS YEAR.FILGOTINIB IS AN INVESTIGATIONAL AGENT AND NOT APPROVED ANYWHERE GLOBALLY.COMPANY DISCUSSED WITH AGENCY PHASE 3 FINCH STUDIES, AS WELL AS ONGOING PHASE 2 MANTA SAFETY STUDY.AS RESULT OF THIS DISCUSSION, A PATH FORWARD HAS BEEN ESTABLISHED TO SUBMIT NDA FOR FILGOTINIB AS TREATMENT FOR RHEUMATOID ARTHRITIS IN 2019.  Full Article

Galapagos NV Net Loss Of EUR 48.7 Million In Q1
Thursday, 25 Apr 2019 04:02pm EDT 

April 25 (Reuters) - Galapagos NV ::GALAPAGOS NV - GROUP REVENUES OF EUR 40.9 MILLION OF Q1.GALAPAGOS NV - NET LOSS OF EUR 48.7 MILLION IN Q1.GALAPAGOS NV - RETAIN GUIDANCE FOR OPERATIONAL CASH BURN BETWEEN EUR 320 - 340 MILLION IN 2019.GALAPAGOS NV - WILL CONTINUE RECRUITMENT IN OUR PROPRIETARY ISABELA AND NOVESA TRIALS, AND PLAN TO FULLY RECRUIT OUR PINTA TRIAL.  Full Article

Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study
Wednesday, 24 Apr 2019 03:21am EDT 

April 24 (Reuters) - GALAPAGOS NV ::ANNOUNCED ON TUESDAY INITIATION OF GECKO.GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.RECRUITMENT WILL TAKE PLACE IN THE U.S. AND CANADA.STUDY IS INTENDED TO SERVE AS AN IND (INVESTIGATIONAL NEW DRUG) OPENER WITH THE U.S. FDA.  Full Article

Galapagos FY Revenue Up At 317.8 Million Euros
Friday, 22 Feb 2019 02:10am EST 

Feb 22 (Reuters) - GALAPAGOS NV ::SAID ON THURSDAY FY REVENUE EUR 317.8 MLN VS EUR 155.9 MLN YR AGO.FY OPERATING LOSS EUR 44.8 MLN VS LOSS OF EUR 89.8 MLN YR AGO.FY NET LOSS EUR 29.3 MLN VS LOSS OF EUR 115.7 MLN YR AGO.CASH, CASH EQUIVALENTS AND RESTRICTED CASH EUR 1.29 BLN AT END-2018 VS EUR 1.15 BLN YR AGO.EXPECTS TO RUN OVER 40 CLINICAL TRIALS THIS YEAR.WE WILL EXPAND OUR COMMERCIAL ORGANIZATION FURTHER AS WE GEAR UP FOR A POTENTIAL MARKET LAUNCH OF FILGOTINIB IN 2020 -CFO.IN 2019 AIMS TO REPORT TOPLINE RESULTS FOR THE FINCH 1 AND FINCH 3 TRIALS IN RA IN Q1.IN 2019 PLANS TO FULLY RECRUIT OUR PHASE 2 PINTA STUDY FOR OUR FULLY PROPRIETARY IPF COMPOUND GLPG1205 AS WELL AS OUR ROCCELLA STUDY IN OA.FOR MOR106 WE PLAN TO START A PHASE 2 TRIAL IN ATD WITH MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS.IN H2 2019 EXPECT PRIMARY ANALYSIS OF THE IGUANA PHASE 2 TRIAL IN ATD AND TOPLINE RESULTS OF SUBCUTANEOUS PHASE 1 BRIDGING STUDY.WE EXPECT AN OPERATIONAL CASH BURN BETWEEN €320 AND €340 MILLION IN 2019.  Full Article

Galapagos S.A. Bob Rajan Joins The Board Of Directors
Thursday, 7 Feb 2019 09:00am EST 

Feb 7 (Reuters) - GALAPAGOS SA ::BOB RAJAN JOINS THE BOARD OF DIRECTORS.  Full Article

Fibrocor And Galapagos Sign Partnership In Fibrosis
Friday, 4 Jan 2019 04:01pm EST 

Jan 4 (Reuters) - Galapagos NV ::REG-FIBROCOR AND GALAPAGOS SIGN PARTNERSHIP IN FIBROSIS.GALAPAGOS NV - GLOBAL PARTNERSHIP FOCUSED ON A NOVEL TARGET FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) AND OTHER INDICATIONS.  Full Article

Galapagos Increases Share Capital Through Warrant Exercises
Friday, 23 Nov 2018 04:01pm EST 

Nov 26 (Reuters) - GALAPAGOS ::ANNOUNCED ON FRIDAY A SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES.ISSUED 30,800 NEW ORDINARY SHARES ON NOV 23 FOR A TOTAL CAPITAL INCREASE (INCLUDING ISSUANCE PREMIUM) OF EUR 381,865.00.CEO ONNO VAN DE STOLPE EXERCISED 15,000 WARRANTS .THREE OTHER EXECUTIVE COMMITTEE MEMBERS EXERCISED AN AGGREGATE NUMBER OF 15,000 WARRANTS.TOTAL SHARE CAPITAL CURRENTLY AMOUNTS TO EUR 294,599,712.11.  Full Article

Reg-Galapagos And Abbvie Restructure Cf Collaboration
Wednesday, 24 Oct 2018 04:02pm EDT 

Oct 24 (Reuters) - Galapagos NV ::REG-GALAPAGOS AND ABBVIE RESTRUCTURE CF COLLABORATION.GALAPAGOS NV - GALAPAGOS WILL RECEIVE AN UPFRONT PAYMENT OF $45 MILLION FROM ABBVIE.GALAPAGOS NV - WILL BE ELIGIBLE TO RECEIVE UP TO $200 MILLION IN ADDITIONAL MILESTONE PAYMENTS FROM ABBVIE.GALAPAGOS NV - ABBVIE FURTHER AGREES TO PAY GALAPAGOS TIERED SINGLE DIGIT ROYALTIES OF GLOBAL COMMERCIAL SALES.GALAPAGOS NV - ABBVIE TAKES OVER ALL PROGRAMS IN CF AND CONTINUES DEVELOPMENT OF A TRIPLE COMBINATION THERAPY FOR CF.GALAPAGOS NV - RETAINS EXCLUSIVE GLOBAL COMMERCIAL RIGHTS TO DEVELOP GLPG2737 IN ALL INDICATIONS OUTSIDE OF CF.GALAPAGOS NV - ABBVIE IS ELIGIBLE FOR FUTURE MILESTONE PAYMENTS AND TIERED SINGLE DIGIT ROYALTIES ON FUTURE GLOBAL COMMERCIAL SALES.GALAPAGOS - ABBVIE WILL OBTAIN EXCLUSIVE WORLDWIDE RIGHTS TO CURRENT CF INVESTIGATIONAL DRUG CANDIDATE PORTFOLIO DEVELOPED BY 2 COS IN COURSE OF COLLABORATION.  Full Article

Galapagos Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis
Saturday, 20 Oct 2018 06:30pm EDT 

Oct 22 (Reuters) - GALAPAGOS NV ::REPORTED TOGETHER WITH GILEAD SCIENCES ON SUNDAY PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS.FINCH 2 STUDY RESULTS DEMONSTRATE SIGNIFICANT IMPROVEMENT IN RHEUMATOID ARTHRITIS SIGNS, SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE.DATA SUGGEST FILGOTINIB HAS A POTENTIAL ROLE IN ADDRESSING IMPORTANT UNMET NEEDS IN THE TREATMENT OF RHEUMATOID ARTHRITIS.POSITIVE EFFICACY DATA FROM FINCH 2 WERE PREVIOUSLY ANNOUNCED IN SEPTEMBER 2018.ADDITIONAL FINCH 2 DATA TO BE PRESENTED INCLUDE POSITIVE RESULTS ACROSS SEVERAL PATIENT-REPORTED HEALTH-RELATED QUALITY OF LIFE MEASURES.FILGOTINIB DEMONSTRATED A SAFETY PROFILE CONSISTENT WITH EARLIER CLINICAL TRIALS.  Full Article

Photo

S&P ends near flat as Citigroup results sink banks; Nasdaq hits new high

NEW YORK The benchmark S&P 500 index ended little changed on Monday after oscillating between positive and negative territory throughout the session after Citigroup Inc kicked off the earnings season with a mixed quarterly report. | Video